Showing 321 - 336 results of 336 for search '"health economics"', query time: 0.06s Refine Results
  1. 321
  2. 322
  3. 323

    Clinical Burden and Healthcare Resource Use of Asthma in Children in the UK by Gouia I, Joulain F, Zhang Y, Morgan CL, Khan AH

    Published 2025-02-01
    “…Imène Gouia,1 Florence Joulain,1 Yi Zhang,2 Christopher Ll Morgan,3 Asif H Khan4 1HEVA (Health Economics and Value Assessment), Sanofi, Gentilly, France; 2Medical Affairs, Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA; 3Epidemiology, Pharmatelligence Ltd, Cardiff, UK; 4Global Medical, Sanofi, Bridgewater, NJ, USACorrespondence: Imène Gouia, Sanofi, 82 Avenue Raspail, Gentilly Cedex, 94255, France, Tel +33786980603, Email Imene.Gouia@sanofi.comBackground: UK pediatric asthma prevalence is among the highest in Europe, and although the clinical and economic burden of asthma in UK adults is well described, childhood asthma data is lacking. …”
    Get full text
    Article
  4. 324
  5. 325
  6. 326
  7. 327
  8. 328
  9. 329
  10. 330
  11. 331
  12. 332

    Early health technology assessment of tongue swab for non-sputum based pulmonary tuberculosis diagnosis in ThailandResearch in context by Langming Mou, Teerawat Wiwatpanit, Apiwat Piriyapol, Puwadol Chawengkul, Janjira Thaipadungpanit, Puttarin Kulchaitanaroaj, Yot Teerawattananon, Yi Wang

    Published 2025-02-01
    “…Methods: We conducted a landscape review, stakeholder consultation, early health economic modeling, and established a Target Product Profile (TPP). …”
    Get full text
    Article
  13. 333

    Non-pharmacological interventions for the reduction and maintenance of blood pressure in people with prehypertension: a systematic review protocol by Paul Rutter, Andrew Clegg, Valerio Benedetto, Caroline Watkins, Nefyn Williams, Joseph Spencer, Lucy Hives, Emma P Bray, Cath Harris, Rachel F Georgiou, Nafisa Iqbal

    Published 2024-01-01
    “…Risk of bias will be evaluated using the Cochrane risk-of-bias tool for RCTs and the Consensus Health Economic Criteria list for economic evaluations. …”
    Get full text
    Article
  14. 334

    Exploring the potential cost-effectiveness and societal burden implications of screening for fracture risk in a UK general radiography setting by E. Söreskog, B. Lopez, T. Bean, P. Lewis, N. Ashley, J. Da Palma Lopes, R. Meertens, A. Ratcliffe

    Published 2025-02-01
    “…Methods The study used a health economic model that compared the health outcomes and costs of screening with IBEX BH versus usual care for men and women aged 50 and older who had a forearm radiograph for any reason. …”
    Get full text
    Article
  15. 335

    Evaluating the cost-effectiveness of prosthetic rehabilitation for partially edentulous teeth in India: A comparative study of Clasp-Retained RPDs, Thermoplastic Resin RPDs, and Ca... by Subhash V, Aswini Kumar K, Vineetha Karuveettil

    Published 2025-03-01
    “…The study adhered to Consolidated Health Economic Evaluation Reporting Standards. Results: Results showed significant differences in OHIP scores between the groups, with CPD offering the highest quality of life, followed by TR-RPD, and MC-RPD. …”
    Get full text
    Article
  16. 336

    Estimating the Cost-Effectiveness of Tumor Treating Fields (TTFields) Therapy with an Immune Checkpoint Inhibitor or Docetaxel in Metastatic Non-Small Cell Lung Cancer by Furnback W, Wu E, Koh CYC, Nino de Rivera Guzman JF, Kruhl C, Kotecha R, Wang BC

    Published 2025-02-01
    “…This study evaluates the cost-effectiveness of TTFields therapy concomitant with immune checkpoint inhibitors (ICIs) or docetaxel.Methods: A model-based health economic evaluation estimated lifetime costs, clinical benefits, and humanistic outcomes of TTFields therapy plus ICI or docetaxel versus ICI or docetaxel alone in metastatic NSCLC. …”
    Get full text
    Article